Cargando…

Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues

Non-viral vectors have emerged as a promising alternative to viral gene delivery systems due to their safer profile. Among non-viral vectors, recently, niosomes have shown favorable properties for gene delivery, including low toxicity, high stability, and easy production. The three main components o...

Descripción completa

Detalles Bibliográficos
Autores principales: AL Qtaish, Nuseibah, Gallego, Idoia, Villate-Beitia, Ilia, Sainz-Ramos, Myriam, López-Méndez, Tania Belén, Grijalvo, Santiago, Eritja, Ramón, Soto-Sánchez, Cristina, Martínez-Navarrete, Gema, Fernández, Eduardo, Puras, Gustavo, Pedraz, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150807/
https://www.ncbi.nlm.nih.gov/pubmed/32106545
http://dx.doi.org/10.3390/pharmaceutics12030198
_version_ 1783521102871396352
author AL Qtaish, Nuseibah
Gallego, Idoia
Villate-Beitia, Ilia
Sainz-Ramos, Myriam
López-Méndez, Tania Belén
Grijalvo, Santiago
Eritja, Ramón
Soto-Sánchez, Cristina
Martínez-Navarrete, Gema
Fernández, Eduardo
Puras, Gustavo
Pedraz, José Luis
author_facet AL Qtaish, Nuseibah
Gallego, Idoia
Villate-Beitia, Ilia
Sainz-Ramos, Myriam
López-Méndez, Tania Belén
Grijalvo, Santiago
Eritja, Ramón
Soto-Sánchez, Cristina
Martínez-Navarrete, Gema
Fernández, Eduardo
Puras, Gustavo
Pedraz, José Luis
author_sort AL Qtaish, Nuseibah
collection PubMed
description Non-viral vectors have emerged as a promising alternative to viral gene delivery systems due to their safer profile. Among non-viral vectors, recently, niosomes have shown favorable properties for gene delivery, including low toxicity, high stability, and easy production. The three main components of niosome formulations include a cationic lipid that is responsible for the electrostatic interactions with the negatively charged genetic material, a non-ionic surfactant that enhances the long-term stability of the niosome, and a helper component that can be added to improve its physicochemical properties and biological performance. This review is aimed at providing recent information about niosome-based non-viral vectors for gene delivery purposes. Specially, we will discuss the composition, preparation methods, physicochemical properties, and biological evaluation of niosomes and corresponding nioplexes that result from the addition of the genetic material onto their cationic surface. Next, we will focus on the in situ application of such niosomes to deliver the genetic material into immune-privileged tissues such as the brain cortex and the retina. Finally, as future perspectives, non-invasive administration routes and different targeting strategies will be discussed.
format Online
Article
Text
id pubmed-7150807
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71508072020-04-20 Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues AL Qtaish, Nuseibah Gallego, Idoia Villate-Beitia, Ilia Sainz-Ramos, Myriam López-Méndez, Tania Belén Grijalvo, Santiago Eritja, Ramón Soto-Sánchez, Cristina Martínez-Navarrete, Gema Fernández, Eduardo Puras, Gustavo Pedraz, José Luis Pharmaceutics Review Non-viral vectors have emerged as a promising alternative to viral gene delivery systems due to their safer profile. Among non-viral vectors, recently, niosomes have shown favorable properties for gene delivery, including low toxicity, high stability, and easy production. The three main components of niosome formulations include a cationic lipid that is responsible for the electrostatic interactions with the negatively charged genetic material, a non-ionic surfactant that enhances the long-term stability of the niosome, and a helper component that can be added to improve its physicochemical properties and biological performance. This review is aimed at providing recent information about niosome-based non-viral vectors for gene delivery purposes. Specially, we will discuss the composition, preparation methods, physicochemical properties, and biological evaluation of niosomes and corresponding nioplexes that result from the addition of the genetic material onto their cationic surface. Next, we will focus on the in situ application of such niosomes to deliver the genetic material into immune-privileged tissues such as the brain cortex and the retina. Finally, as future perspectives, non-invasive administration routes and different targeting strategies will be discussed. MDPI 2020-02-25 /pmc/articles/PMC7150807/ /pubmed/32106545 http://dx.doi.org/10.3390/pharmaceutics12030198 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
AL Qtaish, Nuseibah
Gallego, Idoia
Villate-Beitia, Ilia
Sainz-Ramos, Myriam
López-Méndez, Tania Belén
Grijalvo, Santiago
Eritja, Ramón
Soto-Sánchez, Cristina
Martínez-Navarrete, Gema
Fernández, Eduardo
Puras, Gustavo
Pedraz, José Luis
Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues
title Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues
title_full Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues
title_fullStr Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues
title_full_unstemmed Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues
title_short Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues
title_sort niosome-based approach for in situ gene delivery to retina and brain cortex as immune-privileged tissues
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150807/
https://www.ncbi.nlm.nih.gov/pubmed/32106545
http://dx.doi.org/10.3390/pharmaceutics12030198
work_keys_str_mv AT alqtaishnuseibah niosomebasedapproachforinsitugenedeliverytoretinaandbraincortexasimmuneprivilegedtissues
AT gallegoidoia niosomebasedapproachforinsitugenedeliverytoretinaandbraincortexasimmuneprivilegedtissues
AT villatebeitiailia niosomebasedapproachforinsitugenedeliverytoretinaandbraincortexasimmuneprivilegedtissues
AT sainzramosmyriam niosomebasedapproachforinsitugenedeliverytoretinaandbraincortexasimmuneprivilegedtissues
AT lopezmendeztaniabelen niosomebasedapproachforinsitugenedeliverytoretinaandbraincortexasimmuneprivilegedtissues
AT grijalvosantiago niosomebasedapproachforinsitugenedeliverytoretinaandbraincortexasimmuneprivilegedtissues
AT eritjaramon niosomebasedapproachforinsitugenedeliverytoretinaandbraincortexasimmuneprivilegedtissues
AT sotosanchezcristina niosomebasedapproachforinsitugenedeliverytoretinaandbraincortexasimmuneprivilegedtissues
AT martineznavarretegema niosomebasedapproachforinsitugenedeliverytoretinaandbraincortexasimmuneprivilegedtissues
AT fernandezeduardo niosomebasedapproachforinsitugenedeliverytoretinaandbraincortexasimmuneprivilegedtissues
AT purasgustavo niosomebasedapproachforinsitugenedeliverytoretinaandbraincortexasimmuneprivilegedtissues
AT pedrazjoseluis niosomebasedapproachforinsitugenedeliverytoretinaandbraincortexasimmuneprivilegedtissues